; Decreased VWF levels or defects in VWF function cause von Willebrand disease (VWD) the most common inherited bleeding disorder. The reduced plasma survival of VWF is a novel mechanism causing type 1 VWD (type IC) and may represent 10-15% of type 1 VWD cases. While our studies have defined the characteristic elements of the type IC phenotype, very little is known about the mechanisms governing VWF clearance under normal or pathological conditions. Our goal is to define VWF clearance mechanisms. We have identified many novel mutations in the VWF coding region for VWD patients. These novel sequence variations are distributed throughout all domains within the VWF protein. Our previous expression studies revealed that type 2A VWD results from a complex intersection of mechanisms: defective secretion, multimerization, regulated storage, or ADAMTSI 3 susceptibility. The 2A mutations, when co-expressed with wild-type VWF, appeared to negatively impact at least one mechanism important for normal VWF processing. While decreased secretion and reduced plasma survival have been implicated as mechanisms causing type 1 VWD, the impact of type 1 mutations on multimerization, regulated storage/secretion, and ADAMTSI 3-mediated degradation is not well-defined. We will define the mechanisms causing type 1 VWD and develop a model that would allow one to predict the impact of mutations on VWD phenotype. ADAMTSI 3-mediated proteolysis of VWF clearly plays a crucial role in type 2A VWD. Some studies have suggested that ADAMTSI 3 may also contribute to the type 1 VWD phenotype. A percentage of ADAMTSI 3 is reported to bind to circulating VWF and thus may be cleared quickly in type IC VWD patients. We will determine if type 1 VWF variants have increased susceptibility to ADAMTS-13 proteolysis and examine if ADAMTSI3 levels are reduced in type IC VWD. The knowledge gained from these studies will increase our understanding of mechanisms causing VWD, leading to the development of more effective treatment strategies

Public Health Relevance

This project studies the role of von Willebrand factor (VWF) in von Willebrand disease (VWD). This project will explore the mechanisms causing type 1 VWD, specifically the effect of mutations identified in these patients on VWF production, degradation and clearance. These studies will increase our understanding of mechanisms causing VWD, and will lead to the development of more effective treatment strategies.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Program Projects (P01)
Project #
2P01HL081588-06
Application #
8246609
Study Section
Heart, Lung, and Blood Initial Review Group (HLBP)
Project Start
Project End
Budget Start
2012-02-15
Budget End
2013-01-31
Support Year
6
Fiscal Year
2012
Total Cost
$300,508
Indirect Cost
Name
Medical College of Wisconsin
Department
Type
DUNS #
937639060
City
Milwaukee
State
WI
Country
United States
Zip Code
53226
Goodeve, A C; Pavlova, A; Oldenburg, J (2014) Genomics of bleeding disorders. Haemophilia 20 Suppl 4:50-3
Fahs, Scot A; Hille, Matthew T; Shi, Qizhen et al. (2014) A conditional knockout mouse model reveals endothelial cells as the principal and possibly exclusive source of plasma factor VIII. Blood 123:3706-13
de Brasi, C; El-Maarri, O; Perry, D J et al. (2014) Genetic testing in bleeding disorders. Haemophilia 20 Suppl 4:54-8
Laffan, Mike A; Lester, Will; O'Donnell, James S et al. (2014) The diagnosis and management of von Willebrand disease: a United Kingdom Haemophilia Centre Doctors Organization guideline approved by the British Committee for Standards in Haematology. Br J Haematol 167:453-65
Hampshire, Daniel J; Goodeve, Anne C (2014) p.P2063S: a neutral VWF variant masquerading as a mutation. Ann Hematol 93:505-6
Elbatarny, M; Mollah, S; Grabell, J et al. (2014) Normal range of bleeding scores for the ISTH-BAT: adult and pediatric data from the merging project. Haemophilia 20:831-5
Castaman, G; Hillarp, A; Goodeve, A (2014) Laboratory aspects of von Willebrand disease: test repertoire and options for activity assays and genetic analysis. Haemophilia 20 Suppl 4:65-70
Shida, Yasuaki; Rydz, Natalia; Stegner, David et al. (2014) Analysis of the role of von Willebrand factor, platelet glycoprotein VI-, and ?2?1-mediated collagen binding in thrombus formation. Blood 124:1799-807
Rusu, Luiza; Andreeva, Alexandra; Visintine, David J et al. (2014) G protein-dependent basal and evoked endothelial cell vWF secretion. Blood 123:442-50
Brott, David A; Katein, Anne; Thomas, Heath et al. (2014) Evaluation of von Willebrand factor and von Willebrand factor propeptide in models of vascular endothelial cell activation, perturbation, and/or injury. Toxicol Pathol 42:672-83

Showing the most recent 10 out of 49 publications